Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AMBI

AMBI (AMBI) Stock Price, News & Analysis

AMBI logo

About AMBI Stock (NASDAQ:AMBI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$4.75
$5.20
50-Day Range
N/A
52-Week Range
N/A
Volume
7,220 shs
Average Volume
5,081 shs
Market Capitalization
$275.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Remove Ads
Receive AMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

AMBI Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

AMBI Stock Analysis - Frequently Asked Questions

AMBI (NASDAQ:AMBI) announced its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.03. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.50 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that AMBI investors own include Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Bristol-Myers Squibb (BMY), Broadcom (BRCM), Cytokinetics (CYTK), Delta Air Lines (DAL) and Fortress Biotech (FBIO).

Company Calendar

Last Earnings
5/06/2014
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Sanitary services
Sub-Industry
N/A
Current Symbol
NASDAQ:AMBI
Fax
N/A
Employees
7,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$518.81 million
Cash Flow
$0.78 per share
Price / Cash Flow
6.40
Book Value
$4.90 per share
Price / Book
1.01

Miscellaneous

Free Float
26,606,000
Market Cap
$275.49 million
Optionable
Not Optionable
Beta
0.55
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:AMBI) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners